Organic Cation Transporter Family Research Articles

Expression and clinical significance of organic cation transporter family in glioblastoma multiforme.

Solute carrier (SLC) 22 A1, A2, and A3 are polyspecific transporters transporting organic cations like histamine, serotonin, norepinephrine, dopamine, MPP + , and toxins. The expression of SLC22A1-A3 in cancer is seldom investigated, and the function of SLC22A1-A3 in glioblastoma multiforme (GBM) is never elucidated. In our study, we detected the expression of SLC22A1-A3 in 11 fresh GBMs and tumor-adjacent brain tissues with qPCR, and in 129 paraffin-embedded GBMs with immunohistochemistry (IHC). With chi-square test, we investigated the correlation between expression of SLC22A1-A3 and the clinicopathological factors including patients' age, sex, tumor size, and KPS score. With Kaplan-Meier method and Cox-regression model, we estimated the prognostic significance of SLC22A1-A3 in GBM. SLC22A3 was significantly downregulated in GBMs compared with the tumor-adjacent normal tissues. With univariate survival analyses, we showed that SLC22A3, instead of SLC22A1 and A2, was an independent biomarker predicting favorable prognosis. With multivariate analyses, SLC22A3 was identified as an independent prognostic biomarker indicating the favorable outcome of GBM. SLC22A3 is an independent favorable prognostic biomarker of GBM. Patients with low SLC22A3 may be more high-risk and should receive more intensive post-operational supervision and treatments.

Drosophila SLC22A Transporter Is a Memory Suppressor Gene that Influences Cholinergic Neurotransmission to the Mushroom Bodies

The mechanisms that constrain memory formation are of special interest because they provide insights into the brain's memory management systems and potential avenues for correcting cognitive disorders. RNAi knockdown in the Drosophila mushroom body neurons (MBn) of a newly discovered memory suppressor gene, Solute Carrier DmSLC22A, a member of the organic cation transporter family, enhances olfactory memory expression, while overexpression inhibits it. The protein localizes to the dendrites of the MBn, surrounding the presynaptic terminals of cholinergic afferent fibers from projection neurons (Pn). Cell-based expression assays show that this plasma membrane protein transports cholinergic compounds with the highest affinity among several invitro substrates. Feeding flies choline or inhibiting acetylcholinesterase in Pn enhances memory, an effect blocked by overexpression of the transporter in the MBn. The data argue that DmSLC22A is a memory suppressor protein that limits memory formation by helping to terminate cholinergic neurotransmission at the Pn:MBn synapse.

Expression of choline and acetylcholine transporters in synovial tissue and cartilage of patients with rheumatoid arthritis and osteoarthritis.

Increasing evidence is showing that the non-neuronal cholinergic system plays an important role in the pathology of rheumatoid arthritis (RA). Choline transport into the cell is the rate-limiting step for the synthesis of acetylcholine (ACh), which can be released directly or in vesicles from the cell. However, in the human joint little is known about choline import or the release of ACh from the cell. Thus, we analyze the expression of members of the organic cation transporter (OCT), of the newly discovered choline transporter-like (CTL) family and of classical neuronal components such as the high-affinity choline transporter (CHT1) and the vesicular ACh transporter (VAChT) in the synovium and cartilage of the human hip joint from patients with osteoarthritis (OA) and RA. OCT1, OCT3 and OCTN1 and all members of the CTL family were expressed in synovial and cartilage samples. The expression of CTL1 and CTL2 was localized in synovial macrophages and fibroblasts. CHT1 mRNA expression was detectable only in the synovium, whereas VAChT was completely absent in all samples. Therefore, in the human joint, choline transport into the cell and the release of ACh seems to be mediated mainly by members of the OCT and CTL family. Expression of transporters appears not to be influenced by the pathological state, as no differences have been detected between joints from OA or RA patients. Importantly, however, all necessary components for choline import and the release of non-neuronal ACh are present in the human joint.Electronic supplementary materialThe online version of this article (doi:10.1007/s00441-014-2036-0) contains supplementary material, which is available to authorized users.

The Role of Pharmacogenetics in Drug Disposition and Response of Oral Glucose-Lowering Drugs

The primary goal of type 2 diabetes mellitus (T2DM) disease management is improvement of quality of life and prevention of complications. One way to achieve these goals is improving glycemic control by using different types of oral glucose-lowering medications. Currently seven different pharmacological oral glucose-lowering drug classes are available, each with its own mechanism of action and characteristics regarding absorption, distribution, metabolism, and elimination. Unfortunately, the response to the different types of glucose-lowering medication is highly variable between individuals resulting in unnecessary treatment failure. Genetic factors are thought to contribute to the variability in response and may present an opportunity to improve treatment outcome. In recent years, many efforts were taken to identify genetic variants that influence the pharmacokinetics, pharmacodynamics, and ultimately the therapeutic response of the different oral glucose-lowering drugs. Indeed several genetic variants are associated with the response to oral glucose-lowering drugs. This review comprises current knowledge on genetic variants affecting both pharmacokinetics and pharmacodynamics of oral glucose-lowering drugs. Included variants are located in genes coding for drug transporters, i.e., the organic anion-transporting family and the organic cation transporter family; genes involved in metabolism, i.e., cytochrome P450 superfamily; genes coding for drug receptors; T2DM-associated genes; and genes identified by genome-wide association studies (GWASs). Furthermore, this review provides insight into current status and future directions for personalized medicine in T2DM.

Thiamine is a substrate of organic cation transporters in Caco-2 cells

The aim of this study was to characterize the intestinal absorption of thiamine, by investigating the hypothesis of an involvement of Organic Cation Transporter (OCT) family members in this process. [3H]-T+ uptake was found to be: 1) time-dependent, 2) Na+- and Cl−-dependent, 3) pH-dependent, with uptake increasing with a decrease in extracellular pH and decreasing with a decrease in intracellular pH, 4) inhibited by amiloride, 5) inhibited by the thiamine structural analogues oxythiamine and amprolium, 6) inhibited by the unrelated organic cations MPP+, clonidine, dopamine, serotonin, 7) inhibited by the OCT inhibitors decynium22 and progesterone. Moreover, the dependence of [3H]-T+ uptake on phosphorylation/dephosphorylation mechanisms was also investigated and [3H]-T+ uptake was found to be reduced by PKA activation and protein tyrosine phosphatase and alkaline phosphatase inhibition. In conclusion, our results are compatible with the possibility of thiamine being transported not only by ThTr1 and/or ThTr2, but also by members of the OCT family of transporters (most probably OCT1 and/or OCT3), thus sharing the same transporters with several other organic cations at the small intestinal level.

Expression and characterization of two novel transporter orthologs, BOCT1 and BOCT2

The objective of this study is to characterize two novel members of the organic cation transporter (OCT) family: BOCT1 and BOCT2. Primary aims include the expression of recombinant BOCT1 and BOCT2 protein in cells, functional characterization, and generation of monoclonal antibodies. The novel genes and two technical control transporters, OCT1 and OCTN2, were expressed as fusion proteins, stably transfected into HEK‐293 cells, and assayed for organic cation uptake. OCT1 caused a significant increase in choline (1.5‐fold), tetraethylammonium (2‐fold), and 1‐methyl–4‐phenylpyridinium (40‐fold) uptake, and OCTN2 caused a significant increase in carnitine (12‐fold) uptake. However, BOCT1 and BOCT2 did not show any effect, suggesting that they do not function in organic cation transport despite homology to the OCT family. In preparation for making monoclonal antibodies, a DNA fragment encoding ∼60 amino acids of both BOCT1 and BOCT2 was amplified via PCR and each cloned into the pRSET plasmid vector containing a 6‐His peptide tag sequence. Upon induction in E.coli, peptides accumulated in the insoluble inclusion body fractions, which were solubilized in 8M urea. The inclusion bodies were further purified by metal affinity chromatography, and the ∼12kD peptides were analyzed by SDS‐PAGE. Refolding conditions were optimized, and the peptides were prepared for immunization into mice. Funded by NIH R15 GM070578.

Stress regulated members of the plant organic cation transporter family are localized to the vacuolar membrane

BackgroundIn Arabidopsis six genes group into the gene family of the organic cation transporters (OCTs). In animals the members of the OCT-family are mostly characterized as polyspecific transporters involved in the homeostasis of solutes, the transport of monoamine neurotransmitters and the transport of choline and carnitine. In plants little is known about function, localisation and regulation of this gene family. Only one protein has been characterized as a carnitine transporter at the plasma membrane so far.FindingsWe localized the five uncharacterized members of the Arabidopsis OCT family, designated OCT2-OCT6, via GFP fusions and protoplast transformation to the tonoplast. Expression analysis with RNA Gel Blots showed a distinct, organ-specific expression pattern of the individual genes. With reporter gene fusion of four members we analyzed the tissue specific distribution of OCT2, 3, 4, and 6. In experiments with salt, drought and cold stress, we could show that AtOCT4, 5 and 6 are up-regulated during drought stress, AtOCT3 and 5 during cold stress and AtOCT 5 and 6 during salt stress treatments.ConclusionLocalisation of the proteins at the tonoplast and regulation of the gene expression under stress conditions suggests a specific role for the transporters in plant adaptation to environmental stress.

Transport of Timolol and Tilisolol in Rabbit Corneal Epithelium

The purpose of this study is to characterize the transport of tilisolol and timolol through the corneal epithelium, which is believed to be a tight barrier of ocular drug absorption. Cultured normal rabbit corneal epithelial cells (RCEC) were used to investigate drug transport. Primary RCEC were seeded on a filter membrane of Transwell-COL insert coated with fibronectin and grown in Dulbecco's modified Eagle's medium/nutrient mixture F-12 with various supplements. Beta-blocker permeability through the RCEC layer was measured to assess the transcellular permeability coefficient (P(transcell)) in the absence or presence of inhibitors. The transcellular permeability of tilisolol was dependent on drug concentration although timolol showed no concentration dependency. Tilisolol flux from the apical to the basal side was larger than in the opposite direction although timolol showed no direction dependency. The transcellular permeability of tilisolol from the apical to the basal side was inhibited by sodium azide, tetraethylammonium, quinidine, taurocholic acid, guanidine and carnitine. Tilisolol had an active mechanism in uptake to the corneal epithelium, probably by the organic cation transporter family, although timolol predominantly permeated via passive diffusion. This RCEC system was useful to characterize the ocular permeation mechanism of drugs.

Guanidine Transport across the Apical and Basolateral Membranes of Human Intestinal Caco-2 Cells Is Mediated by Two Different Mechanisms

The functional characteristics of the intestinal absorption and secretion of guanidine as a model of a nutritionally and metabolically essential organic cation were examined in the Caco-2 human intestinal cell line. Both apical and basolateral transport of [14C]-guanidine were studied using Caco-2 cells grown on polycarbonate permeable membranes. The basolateral-to-apical flux of [14C]-guanidine (i.e., its secretion) was quantitatively higher than the apical-to-basolateral transport (i.e., its absorption). When Na+ was replaced by K+ or Li+, both apical and basolateral accumulation were significantly inhibited. Studies using the cell monolayers and apical membrane vesicles obtained from Caco-2 cells showed a potential-independent mechanism of guanidine apical uptake and efflux. Conversely, basolateral uptake and efflux were membrane potential dependent. Kinetic analysis revealed that both saturable and nonsaturable mechanisms accounted for the apical and basolateral accumulations. The [14C]-guanidine efflux from cells through the apical and basolateral membranes was significantly reduced at 4 degrees C, suggesting carrier-mediated mechanisms. Moreover, the apical efflux was stimulated by an inwardly directed H+ gradient. Influx and efflux of [14C]-guanidine were unaffected by the presence of tetraethylammonium, cimetidine or decynium-22 in the donor compartment. Only quinine significantly reduced [14C]-guanidine entrance through apical and basolateral membranes and its exit through the basolateral membrane. In conclusion, our results suggest that the influx and the efflux through the apical membrane is mediated by different transporters, whereas transport across the basolateral membrane is mediated by a member of the organic cation transporter family with high affinity for guanidine.

Functional and pharmacological characterization of human Na(+)-carnitine cotransporter hOCTN2.

L-Carnitine is essential for the translocation of acyl-carnitine into the mitochondria for beta-oxidation of long-chain fatty acids. It is taken up into the cells by the recently cloned Na(+)-driven carnitine organic cation transporter OCTN2. Here we expressed hOCTN2 in Xenopus laevis oocytes and investigated with two-electrode voltage- clamp and flux measurements its functional and pharmacological properties as a Na(+)-carnitine cotransporter. L-carnitine transport was electrogenic. The L-carnitine-induced currents were voltage and Na(+) dependent, with half-maximal currents at 0.3 +/- 0.1 mM Na(+) at -60 mV. Furthermore, L-carnitine-induced currents were pH dependent, decreasing with acidification. In contrast to other members of the organic cation transporter family, hOCTN2 functions as a Na(+)-coupled carnitine transporter. Carnitine transport was stereoselective, with an apparent Michaelis-Menten constant (K(m)) of 4.8 +/- 0.3 microM for L-carnitine and 98.3 +/- 38.0 microM for D-carnitine. The substrate specificity of hOCTN2 differs from rOCT-1 and hOCT-2 as hOCTN2 showed only small currents with classic OCT substrates such as choline or tetraethylammonium; by contrast hOCTN2 mediated transport of betaine. hOCTN2 was inhibited by several drugs known to induce secondary carnitine deficiency. Most potent blockers were the antibiotic emetine and the ion channel blockers quinidine and verapamil. The apparent IC(50) for emetine was 4.2 +/- 1.2 microM. The anticonvulsant valproic acid did not induce a significant inhibition of carnitine transport, pointing to a different mode of action. In summary, hOCTN2 mediates electrogenic Na(+)-dependent stereoselective high-affinity transport of L-carnitine and Na(+). hOCTN2 displays transport properties distinct from other members of the OCT family and is directly inhibited by several substances known to induce systemic carnitine deficiency.

Molecular biology of multispecific organic anion transporter family (OAT family)

It has been predicted that a variety of organic anions of endogenous and exogenous origin are secreted by the renal proximal tubules via the p-aminohippurate (PAH) transport system. Organic anions are taken up from the peritubular plasma by the basolateral PAH transporter, and subsequently excreted into the urine by distinct organic anion transporter(s) in the luminal membrane. In 1997, we isolated the PAH transporter, organic anion transporter 1 (OAT1), from the rat kidney by the expression cloning method. OAT1 is a 551-amino-acid residue protein with 12 putative membrane spanning domains. It is exclusively expressed in the kidney, and is localized to the basolateral membrane of the cells of the middle portion of the proximal tubule, S2. OAT1 is a sodium-independent, organic anion/dicarboxylateexchanger, and mediates the transport of various organic anions. We have also identified two other isoforms of OAT. Rat OAT2 is predominantly expressed in the liver, while rat OAT3 is expressed in the liver, kidney, brain, and eyes. The isoforms exhibit overlapping but distinct substrate specificities. Interestingly, the members of the OAT family are structurally related to the members of the organic cation transporter (OCT) family. In addition, we have identified a membrane protein showing homology to both OATs and OCTs. This clone (CT1) mediated the transport of carnitine, a zwitterion. In this article, we describe the structure and functions of the members of the OAT family in association with these features in members of the OCT family and the zwitterion transporter.

Cloning of the Human Thiamine Transporter, a Member of the Folate Transporter Family

We have isolated a cDNA from human placenta, which, when expressed heterologously in mammalian cells, mediates the transport of the water-soluble vitamin thiamine. The cDNA codes for a protein of 497 amino acids containing 12 putative transmembrane domains. Northern blot analysis indicates that this transporter is widely expressed in human tissues. When expressed in HeLa cells, the cDNA induces the transport of thiamine (K(t) = 2.5 +/- 0.6 microM) in a Na(+)-independent manner. The cDNA-mediated transport of thiamine is stimulated by an outwardly directed H(+) gradient. Substrate specificity assays indicate that the transporter is specific to thiamine. Even though thiamine is an organic cation, the cDNA-induced thiamine transport is not inhibited by other organic cations. Similarly, thiamine is not a substrate for the known members of mammalian organic cation transporter family. The thiamine transporter gene, located on human chromosome 1q24, consists of 6 exons and is most likely the gene defective in the metabolic disorder, thiamine-responsive megaloblastic anemia. At the level of amino acid sequence, the thiamine transporter is most closely related to the reduced-folate transporter and thus represents the second member of the folate transporter family.

CDNA Sequence, Transport Function, and Genomic Organization of Human OCTN2, a New Member of the Organic Cation Transporter Family

We have cloned OCTN2, a new member of the organic cation transporter family, from a human placental trophoblast cell line. The hOCTN2 cDNA codes for a protein of 557 amino acids with twelve putative transmembrane domains. Theoctn2gene, located on human chromosome 5q31, consists of ten exons. The OCTN2-specific transcript, 3.5 kb in size, is expressed widely in human tissues and in cell lines of human origin. At the level of amino acid sequence, OCTN2 is more closely related to OCTN1 than to OCT1, OCT2 and OCT3. When expressed heterologously in HeLa cells, OCTN2 mediates the transport of tetraethylammonium, a prototypical organic cation, in a pH-dependent manner. Several organic cations, including the neurotoxins 1-methyl-4-phenylpyridinium, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, and methamphetamine, compete for the OCTN2-mediated transport process.

Molecular Cloning and Characterization of NKT, a Gene Product Related to the Organic Cation Transporter Family That Is Almost Exclusively Expressed in the Kidney

We have identified a gene product (NKT) encoding an apparently novel transcript that appears to be related to the organic ion transporter family and is expressed almost exclusively in the kidney. Analysis of the deduced 546-amino acid protein sequence indicates that NKT is a unique gene product which shares a similar transmembrane domain hydropathy profile as well as transporter-specific amino acid motifs with a variety of bacterial and mammalian nutrient transporters. Nevertheless, the overall homology of NKT to two recently cloned organic ion transport proteins (NLT and OCT-1) is significantly greater; together these three gene products may represent a new subgroup of transporters. The NKT was characterized further with respect to its tissue distribution and its expression during kidney development. A 2.5-kilobase transcript was found in kidney and at much lower levels in brain, but not in a number of other tissues. Studies on the embryonic kidney indicate that the NKT transcript is developmentally regulated with significant expression beginning at mouse gestational day 18 and rising just before birth, consistent with a role in differentiated kidney function. Moreover, in situ hybridization detected specific signals in mouse renal proximal tubules. NKT was mapped by linkage disequilibrium to mouse chromosome 19, the same site to which several mouse mutations localize, including that for osteochondrodystrophy (ocd). Although initial experiments in a Xenopus oocyte expression system failed to demonstrate transport of known substrates for OCT-1, the homology to OCT-1 and other transporters, along with the proximal tubule localization, raise the possibility that this gene may play a role in organic solute transport or drug elimination by the kidney.